Basiliximab is effective for erosive lichen planus [4]

Archives of Dermatology

Volumn 138, Issue 8, 2002, Pages 1100-1101

  Rebora, Alfredo ^a   Parodi, Aurora ^a   Murialdo, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ANTIBODY;

AGED; AUTOIMMUNE DISEASE; CASE REPORT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; LICHEN PLANUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0036342348     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.138.8.1100     Document Type: Letter

References (4)

1. Administration of DAB3891L-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial
2. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies
3. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
4. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)